Scopus
🔓 Açık Erişim YÖKSİS Eşleşti
Can Dynamic Susceptibility Contrast Perfusion Imaging be Utilized to Detect Isocitrate Dehydrogenase Gene Mutation in Gliomas?
Turkish Neurosurgery · Ocak 2022
YÖKSİS Kayıtları
Can Dynamic Susceptibility Contrast Perfusion Imaging be Utilized to Detect Isocitrate Dehydrogenase Gene Mutation in Gliomas?
TURKISH NEUROSURGERY · 2022 SCI-Expanded
DOÇENT EMİNE UYSAL →
Can dynamic susceptibility contrast perfusion imaging be utilized to detect isocitrate dehydrogenase gene mutation in gliomas?
Turk Neurosurg · 2022 SCI-Expanded
PROFESÖR MEHMET SEDAT DURMAZ →
Can Dynamic Susceptibility Contrast Perfusion Imaging be Utilized to Detect Isocitrate Dehydrogenase Gene Mutation in Gliomas?
TURKISH NEUROSURGERY · 2022 SCI-Expanded
PROFESÖR MEHMET SEDAT DURMAZ →
Can Dynamic Susceptibility Contrast Perfusion Imaging be Utilized to Detect Isocitrate Dehydrogenase Gene Mutation in Gliomas?
TURKISH NEUROSURGERY · 2022 SCI-Expanded
DOÇENT ABİDİN KILINÇER →
Can Dynamic Susceptibility Contrast Perfusion Imaging be Utilized to Detect Isocitrate Dehydrogenase Gene Mutation in Gliomas?
TURKISH NEUROSURGERY · 2022 SCI
DOÇENT MERT ŞAHİNOĞLU →
Can Dynamic Susceptibility Contrast Perfusion Imaging be Utilized to Detect Isocitrate Dehydrogenase Gene Mutation in Gliomas?
TURKISH NEUROSURGERY · 2022 SCI-Expanded
DOÇENT HAKAN CEBECİ →
Can dynamic susceptibility contrast perfusion imaging be utilized to detect isocitrate dehydrogenase gene mutation in gliomas?
Turk Neurosurg · 2022 SCI-Expanded
DOKTOR ÖĞRETİM ÜYESİ NUSRET SEHER →
Makale Bilgileri
DergiTurkish Neurosurgery
Yayın TarihiOcak 2022
Cilt / Sayfa32 · 826-833
Scopus ID2-s2.0-85138158757
Erişim🔓 Açık Erişim
Özet
AIM: To explore the ability of dynamic susceptibility contrast perfusion imaging (DSC-PI) to detect isocitrate dehydrogenase (IDH) gene mutation in gliomas. MATERIAL and METHODS: Preoperative DSC-PI data on histopathologically proven gliomas obtained between January 2015 and December 2019 were reviewed retrospectively. All magnetic resonance imaging (MRI) examinations were performed using a 1.5-T scanner. The maximum relative cerebral blood volume (rCBVmax), percentage signal recovery (PSR), and normalized PSR of tumor cores were calculated. Differences in these values between IDH-mutant and wild-type gliomas were compared, and receiver operating characteristic curves were generated. RESULTS: The patients (32 females, 47 males) were aged 21–76 years (mean 50.7 ± 15 years). The rCBVmax and all PSR values differed significantly between patients with IDH-mutant and those with wild-type tumors (p<0.01 for all comparisons). CONCLUSION: The rCBVmax and PSR values obtained by DSC-PI may facilitate noninvasive detection of the IDH mutation status of gliomas. PSR provided more reliable values for differentiation of IDH-mutant gliomas from wild-type gliomas.
Yazarlar (10)
1
Abidin Kılınçer
2
Hakan Cebeci
3
N. Seher
ORCID: 0000-0003-2296-556X
4
Mehmet Sedat Durmaz
ORCID: 0000-0002-1340-2477
5
Emine Uysal
6
Mert Sahinoglu
ORCID: 0000-0003-0633-8304
7
Ender Koktekir
8
Hakan Karabagli
9
Pınar Karabağlı
ORCID: 0000-0002-5558-0175
10
Y. Paksoy
Anahtar Kelimeler
Glioma
Isocitrate dehydrogenase
Magnetic resonance imaging
Mutation
Perfusion
Kurumlar
Hamad Medical Corporation
Doha Qatar
Qatar University
Doha Qatar
Selçuk Tip Fakültesi
Konya Turkey
Metrikler
1
Atıf
10
Yazar
5
Anahtar Kelime